Biocon Q4 net profit falls 56.8% to ₹198.6 crore on exceptional charges
Synopsis
Biocon's Q4 profit collapsed 56.8% to ₹198.6 crore — not because the business is broken, but because exceptional charges, including those from the new labour code, hit hard. Revenue grew, leadership changed, and the company is calling it a 'pivotal year of integration'. The real question is whether FY27 normalises the bottom line.
Key Takeaways
Biocon reported a 56.8% YoY drop in Q4 consolidated net profit to ₹198.6 crore for the quarter ended 31 March 2026 .
Exceptional charges of ₹80.4 crore , including costs from the new labour code , weighed heavily on the bottom line.
Q4 consolidated revenue from operations rose to ₹4,516.6 crore from ₹4,417 crore in the year-ago period.
Full-year FY26 net profit fell to ₹368.8 crore from ₹1,429.4 crore in FY25; annual revenue climbed to ₹16,927 crore .
Shreehas Tambe took charge as CEO and Managing Director from 1 April 2026 ; Kedar Upadhye appointed as CFO.
Board recommended a final dividend of 50 paise per share (face value ₹5 ) for FY26, subject to shareholder approval.
Biocon Limited on Friday, 8 May 2026, reported a 56.8% year-on-year decline in consolidated net profit to ₹198.6 crore for the fourth quarter ended 31 March 2026, dragged by exceptional expenses — including charges arising from the implementation of the new labour code. The biotechnology major had posted a consolidated net profit of ₹459.4 crore in the corresponding quarter of the previous financial year, according to a regulatory filing.
Revenue Rises Despite Profit Pressure
Despite the sharp bottom-line decline, Biocon's consolidated revenue from operations grew to ₹4,516.6 crore in Q4 FY26, up from ₹4,417 crore in the year-ago quarter. Total expenses for the period, however, rose to ₹4,241.2 crore compared to ₹3,987.5 crore in the same quarter last year, squeezing margins considerably.
Exceptional Items Weigh on the Quarter
The company disclosed an exceptional item outgo of ₹80.4 crore during the quarter under various heads, with the new labour code implementation cited as a key contributor to the one-time impact. Such exceptional charges are typically non-recurring but can significantly distort a quarter's reported profitability. This is notably the second consecutive quarter in which Biocon has flagged integration and transition-related costs as a drag on earnings.
Full-Year Performance: Profit Slump, Revenue Climb
For the full financial year FY2025-26, Biocon's consolidated net profit dropped sharply to ₹368.8 crore from ₹1,429.4 crore in FY25 — a decline of nearly 74% on an annual basis. In contrast, annual consolidated revenue from operations climbed to ₹16,927 crore from ₹15,261.7 crore in the previous fiscal, reflecting underlying business growth even as profitability came under pressure.
Leadership Speaks: 'Resilience and Disciplined Execution'
Commenting on the results, Kiran Mazumdar-Shaw, Executive Chairperson, said the company ended FY26 on a strong note despite operating in a challenging geopolitical environment.
Point of View
But stripping out the exceptional items reveals a company whose revenue engine is actually accelerating — ₹16,927 crore in FY26 versus ₹15,261.7 crore in FY25. The deeper concern is that the annual profit erosion, from ₹1,429.4 crore to ₹368.8 crore, goes well beyond one quarter's exceptional charges, suggesting that integration costs and margin compression are structural, not episodic. The leadership transition — a new CEO and CFO simultaneously — adds execution risk at precisely the moment Biocon needs stability. Investors will be watching whether FY27 guidance, once issued, reflects genuine normalisation or another round of 'pivotal year' hedging.
NationPress
12 May 2026
Frequently Asked Questions
Why did Biocon's Q4 profit fall so sharply?
Biocon's Q4 FY26 consolidated net profit fell 56.8% to ₹198.6 crore primarily due to exceptional charges of ₹80.4 crore, including costs arising from the implementation of the new labour code. Total expenses for the quarter also rose to ₹4,241.2 crore from ₹3,987.5 crore in the year-ago period.
How did Biocon's revenue perform in Q4 FY26?
Despite the profit decline, Biocon's consolidated revenue from operations rose to ₹4,516.6 crore in Q4 FY26, up from ₹4,417 crore in the same quarter last year, indicating continued business growth.
What was Biocon's full-year FY26 financial performance?
For the full year FY2025-26, Biocon's consolidated net profit dropped to ₹368.8 crore from ₹1,429.4 crore in FY25, while annual revenue from operations grew to ₹16,927 crore from ₹15,261.7 crore in the previous fiscal.
Who are Biocon's new top executives?
Shreehas Tambe assumed charge as CEO and Managing Director of Biocon from 1 April 2026, while Kedar Upadhye has been appointed as the company's Chief Financial Officer, marking a significant leadership transition for the biotechnology major.
What dividend has Biocon declared for FY26?
Biocon's board has recommended a final dividend of 50 paise per equity share with a face value of ₹5 each for FY26. The dividend is subject to shareholders' approval at the upcoming annual general meeting.
